KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Free Cash Flow (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Free Cash Flow data on record, last reported at $450.9 million in Q4 2025.

  • For Q4 2025, Free Cash Flow rose 354.31% year-over-year to $450.9 million; the TTM value through Dec 2025 reached $1.4 billion, up 394.1%, while the annual FY2025 figure was $1.6 billion, 450.26% up from the prior year.
  • Free Cash Flow reached $450.9 million in Q4 2025 per EW's latest filing, down from $516.2 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $531.9 million in Q3 2021 and bottomed at -$177.3 million in Q4 2024.
  • Average Free Cash Flow over 5 years is $244.8 million, with a median of $251.3 million recorded in 2022.
  • The widest YoY moves for Free Cash Flow: up 2100.7% in 2024, down 467.08% in 2024.
  • A 5-year view of Free Cash Flow shows it stood at $373.6 million in 2021, then plummeted by 42.75% to $213.9 million in 2022, then plummeted by 77.42% to $48.3 million in 2023, then tumbled by 467.08% to -$177.3 million in 2024, then skyrocketed by 354.31% to $450.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Free Cash Flow were $450.9 million in Q4 2025, $516.2 million in Q3 2025, and $240.9 million in Q2 2025.